These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24619377)

  • 1. Prostate cancer: cabozantinib reduces pain and narcotic use in men with CRPC.
    Clyne M
    Nat Rev Urol; 2014 Apr; 11(4):188. PubMed ID: 24619377
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.
    Basch E; Autio KA; Smith MR; Bennett AV; Weitzman AL; Scheffold C; Sweeney C; Rathkopf DE; Smith DC; George DJ; Higano CS; Harzstark AL; Sartor AO; Gordon MS; Vogelzang NJ; de Bono JS; Haas NB; Corn PG; Schimmoller F; Scher HI
    Eur Urol; 2015 Feb; 67(2):310-8. PubMed ID: 24631409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.
    Smith MR; Sweeney CJ; Corn PG; Rathkopf DE; Smith DC; Hussain M; George DJ; Higano CS; Harzstark AL; Sartor AO; Vogelzang NJ; Gordon MS; de Bono JS; Haas NB; Logothetis CJ; Elfiky A; Scheffold C; Laird AD; Schimmoller F; Basch EM; Scher HI
    J Clin Oncol; 2014 Oct; 32(30):3391-9. PubMed ID: 25225437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma.
    Pinto A
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):219-22. PubMed ID: 24202668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Commentary on "Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial." Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, SchoffskiSchöffski P, Scheffold C, Weitzman AL, Hussain M, University of Michigan, Ann Arbor, MI. J Clin Oncol 2013;31(4):412-9. doi: 10.1200/JCO.2012.45.0494. Epub 2012 Nov 19.
    Trump DL
    Urol Oncol; 2013 Nov; 31(8):1848. PubMed ID: 24210087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
    Smith DC; Smith MR; Sweeney C; Elfiky AA; Logothetis C; Corn PG; Vogelzang NJ; Small EJ; Harzstark AL; Gordon MS; Vaishampayan UN; Haas NB; Spira AI; Lara PN; Lin CC; Srinivas S; Sella A; Schöffski P; Scheffold C; Weitzman AL; Hussain M
    J Clin Oncol; 2013 Feb; 31(4):412-9. PubMed ID: 23169517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current role of cabozantinib in metastatic castration-resistant prostate cancer.
    Fay AP; Albiges L; Bellmunt J
    Expert Rev Anticancer Ther; 2015 Feb; 15(2):151-6. PubMed ID: 25586337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabozantinib in prostate cancer: the beginning of a precision paradigm?
    Goodin S; DiPaola RS
    J Clin Oncol; 2013 Feb; 31(4):401-3. PubMed ID: 23248244
    [No Abstract]   [Full Text] [Related]  

  • 9. Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials.
    Sonpavde GP; Pond GR; Fizazi K; de Bono JS; Basch EM; Scher HI; Smith MR
    Eur Urol Oncol; 2020 Aug; 3(4):540-543. PubMed ID: 31412002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer.
    Di Nunno V; Cimadamore A; Santoni M; Scarpelli M; Fiorentino M; Ciccarese C; Iacovelli R; Cheng L; Lopez-Beltran A; Massari F; Montironi R
    Future Oncol; 2018 Oct; 14(25):2559-2564. PubMed ID: 30141348
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.
    Smith M; De Bono J; Sternberg C; Le Moulec S; Oudard S; De Giorgi U; Krainer M; Bergman A; Hoelzer W; De Wit R; Bögemann M; Saad F; Cruciani G; Thiery-Vuillemin A; Feyerabend S; Miller K; Houédé N; Hussain S; Lam E; Polikoff J; Stenzl A; Mainwaring P; Ramies D; Hessel C; Weitzman A; Fizazi K
    J Clin Oncol; 2016 Sep; 34(25):3005-13. PubMed ID: 27400947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cabozantinib as a novel therapy for renal cell carcinoma.
    Vaishampayan U
    Curr Oncol Rep; 2013 Apr; 15(2):76-82. PubMed ID: 23292795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma.
    Lendvai N; Yee AJ; Tsakos I; Alexander A; Devlin SM; Hassoun H; Korde N; Lesokhin AM; Landau H; Mailankody S; Koehne G; Chung DJ; Landgren O; Raje NS; Giralt S
    Blood; 2016 May; 127(19):2355-6. PubMed ID: 27020089
    [No Abstract]   [Full Text] [Related]  

  • 14. Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).
    Bowles DW; Kessler ER; Jimeno A
    Drugs Today (Barc); 2011 Nov; 47(11):857-68. PubMed ID: 22146228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of weekly and daily recall of pain as an endpoint in a randomized phase 3 trial of cabozantinib for metastatic castration-resistant prostate cancer.
    Schaffer EM; Basch EM; Schwab GM; Bennett AV
    Clin Trials; 2021 Aug; 18(4):408-416. PubMed ID: 33884929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial.
    Leibowitz-Amit R; Pintilie M; Khoja L; Azad AA; Berger R; Laird AD; Aftab DT; Chi KN; Joshua AM
    J Transl Med; 2016 Jan; 14():12. PubMed ID: 26762579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The changing landscape in metastatic castration-resistant prostate cancer.
    Leibowitz-Amit R; Joshua AM
    Curr Opin Support Palliat Care; 2013 Sep; 7(3):243-8. PubMed ID: 23817317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib.
    Lacy SA; Miles DR; Nguyen LT
    Clin Pharmacokinet; 2017 May; 56(5):477-491. PubMed ID: 27734291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabozantinib as an emerging treatment for sarcoma.
    Schöffski P; Blay JY; Ray-Coquard I
    Curr Opin Oncol; 2020 Jul; 32(4):321-331. PubMed ID: 32541320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabozantinib in ovarian clear cell cancers: UnMET expectations.
    Secord AA; Previs RA; Nixon AB
    Gynecol Oncol; 2018 Jul; 150(1):1-2. PubMed ID: 29935857
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.